Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon
- PMID: 29955510
- PMCID: PMC6007569
- DOI: 10.9740/mhc.2017.05.124
Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon
Abstract
Introduction: This chart review utilizes readmission rates and mean time to readmission as markers of drug efficacy to compare different categories of long-acting injectable antipsychotics (LAIAs), antipsychotic polypharmacy, and clozapine to oral antipsychotic monotherapy (OM) at a state psychiatric hospital in Oregon (Oregon State Hospital).
Methods: Charts were reviewed for patients discharged between October 20, 2011, and September 23, 2015, with a diagnosis of schizophrenia spectrum or mood disorder. Admission dates, discharge dates, and discharge antipsychotics were reviewed for each patient dating back to 1991. Discharge antipsychotics were categorized into groupings of LAIAs, antipsychotic polypharmacy, and clozapine and compared with OM to assess readmission data within 1, 3, and 5 years of discharge. The primary end point was readmission rate, measured as a percentage, and the secondary end point was mean time to readmission (MTR), measured in days.
Results: Of 1088 patients reviewed, there were 2031 patient discharges associated with antipsychotic agents and 1258 readmissions. Patients discharged on LAIA monotherapy or clozapine generally had a lower readmission rate, and patients discharged on antipsychotic polypharmacy generally had a higher readmission rate. Statistical significance for these findings varied over time frames and subgroup analyses. The most notable finding for the secondary end point was a significantly shorter MTR for patients discharged on clozapine for all diagnoses and the subgroup analysis of schizoaffective disorder.
Discussion: These results are only a reflection of the patient population at this hospital, and additional reviews at other facilities with different patient characteristics could clarify applicability to other patient populations.
Keywords: antipsychotic drug; antipsychotic polypharmacy; clozapine; long-acting injectable antipsychotic; psychiatric readmission; psychiatric recidivism.
Conflict of interest statement
Disclosures: The authors have no conflicts of interest to declare.
Similar articles
-
Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study.Acta Med Acad. 2017 Nov;46(2):133-144. doi: 10.5644/ama2006-124.198. Acta Med Acad. 2017. PMID: 29338277
-
Comparison of Psychiatric Readmission Rates for Child and Adolescent Patients on Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics: A Mirror Study.J Child Adolesc Psychopharmacol. 2025 Mar;35(2):87-91. doi: 10.1089/cap.2024.0072. Epub 2024 Nov 29. J Child Adolesc Psychopharmacol. 2025. PMID: 39611893
-
Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder.Ment Health Clin. 2016 Aug 31;6(5):254-259. doi: 10.9740/mhc.2016.09.254. eCollection 2016 Sep. Ment Health Clin. 2016. PMID: 29955479 Free PMC article.
-
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].Encephale. 2005 Mar-Apr;31(2):235-46. doi: 10.1016/s0013-7006(05)82390-5. Encephale. 2005. PMID: 15959450 Review. French.
-
[Antipsychotics in bipolar disorders].Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
Cited by
-
Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification.BMC Psychiatry. 2019 Feb 21;19(1):78. doi: 10.1186/s12888-019-2056-0. BMC Psychiatry. 2019. PMID: 30791883 Free PMC article.
-
Readmission Rates of Patients Discharged on Antipsychotic Polypharmacy Compared to Antipsychotic Monotherapy.Community Ment Health J. 2023 Apr;59(3):507-511. doi: 10.1007/s10597-022-01034-5. Epub 2022 Oct 15. Community Ment Health J. 2023. PMID: 36242684
-
Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics.BJPsych Open. 2021 Aug 16;7(5):e149. doi: 10.1192/bjo.2021.982. BJPsych Open. 2021. PMID: 34747353 Free PMC article.
References
-
- Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. . Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40 1: 192- 213. DOI: 10.1093/schbul/sbs150. PubMed PMID: 23256986. - DOI - PMC - PubMed
-
- Lafeuille MH, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. . Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013; 13: 221 DOI: 10.1186/1471-244X-13-221. PubMed PMID: 24016390; PubMed Central PMCID: PMC3847215. - DOI - PMC - PubMed
-
- Conley RR, Love RC, Kelly DL, Bartko JJ. . Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry. 1999; 156 6: 863- 8. DOI: 10.1176/ajp.156.6.863. PubMed PMID: 10360124. - DOI - PubMed
-
- Werneck AP, Hallak JC, Nakano E, Elkis H. . Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res. 2011; 188 3: 315- 9. DOI: 10.1016/j.psychres.2011.04.004. - DOI - PubMed
-
- Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowics A, Lauriello J, et al. . Comparison of SGA oral medications and long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015; 41 2: 449- 59. DOI: 10.1093/schbul/sbu067. PubMed PMID: 24870446. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources